Assignee
ASKLEPIOS BIOPHARMACEUTICAL INC
US·7 granted patents·34 pending applications·9 citations·filing 2014–2025
Top patents by PatentIndex Score
41 records- 0193US9506052B2Modified factor VIII and factor IX genesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2014·Granted Nov 29, 2016·9 cites·4 claims
- 0276US2022389456A1Modified soluble vegf receptor-1 genes and vectors for gene therapyASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 0373US11414678B2Modified soluble VEGF receptor-1 genes and vectors for gene therapyASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Granted Aug 16, 2022·0 cites·20 claims
- 0471US2025121097A1Methods of recombinant adeno-associated virus kidney administrationASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 0567US11268089B2Method for the construction of specific promotersASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Granted Mar 8, 2022·0 cites·15 claims
- 0666US12036287B2Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Granted Jul 16, 2024·0 cites·14 claims
- 0765US2025222072A1Methods and compositions for the treatment of parkinson's diseaseASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 0864US2025213726A1Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modificationsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 0960US2025163457A1Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapyASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 1057US2024084268A1Method for purifying recombinant viral particlesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 1156US2025109398A1Compositions for treating neurological diseaseASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 1256US2023340470A1Methods for treating huntington's diseaseASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 1355US12241115B2Methods and compositions for enriching nucleic acidsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Granted Mar 4, 2025·0 cites·17 claims
- 1455US2022243212A1Production of vectors using phage origin of replicationASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 1554US2023365963A1Methods for treating neurological diseaseASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 1653US11235070B2Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Granted Feb 1, 2022·0 cites·20 claims
- 1753US2023048994A1Recombinant aav productionASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 1853US2022364113A1Host systems comprising inhibitors of a gene-editing protein for production of viral vectorsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 1953US2023374542A1Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)ASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2052US2023149428A1Method of treating gene therapy associated toxicity with antibioticsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2152US2025283148A1Methods and compositions for enriching nucleic acidsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2025·Application pending·0 cites
- 2251US2021269828A1Vectors for gene delivery that persist within cellsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 2351US2023056396A1Systems and methods for synthetic regulatory sequence design or productionASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2450US2023167458A1Forskolin-inducible promoters and hypoxia-inducible promotersASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2550US2025129381A1Regulatory nucleic acid sequencesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 2649US2023407326A1Inducible promoter for viral vector productionASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2749US2023407327A1Inducible promoter for viral vector productionASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2849US2023374526A1Forskolin-inducible promoters and hypoxia-inducible promotersASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2948US2024374843A1Cannula assemblyASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3048US2021032660A1Liver tropic recombinant aav6 vectors that evade neutralizationASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 3148US2023037026A1Method for identifying regulatory elements conformationallyASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 3245US2023340460A1Method for identifying regulatory elementsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 3345US2023321279A1Regulatory nucleic acid sequencesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3445US2024189447A1Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral responseASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3544US2023038520A1Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disordersASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 3643US2023143758A1Regulatory nucleic acid sequencesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3742US2023233710A1Regulatory nucleic acid sequencesASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 3840US2022152221A1A method of treating cystic fibrosisASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 3937US2022133906A1Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal teargeting sequenceASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 4037US2022054656A1Therapeutic adeno-associated virus for treating pompe diseaseASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 4132US11492618B2Expression control using a regulatable intronASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2018·Granted Nov 8, 2022·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when ASKLEPIOS BIOPHARMACEUTICAL INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →